NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Phase 3

Completed

Conditions: Mucinous Adenocarcinoma of the Colon
Mucinous Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IIIA Colon Cancer
Stage IIIA Rectal Cancer
Stage IIIB Colon Cancer
Stage IIIB Rectal Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: oxaliplatin
Procedure: quality-of-life assessment
Drug: leucovorin calcium
Drug: fluorouracil

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 560

Registration Number: NCT00005036

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

Phase 2

Terminated

Conditions: Colorectal Cancer

Interventions: Biological: trastuzumab
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00006015

Locations: 🇺🇸
Vermont Cancer Center, Burlington, Vermont, United States
🇺🇸
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States

and more 44 locations

Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 2

Completed

Conditions: Juvenile Myelomonocytic Leukemia

Interventions: Drug: tipifarnib
Drug: isotretinoin
Drug: fludarabine phosphate
Drug: cytarabine
Radiation: radiation therapy
Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Procedure: allogeneic bone marrow transplantation
Procedure: double-unit umbilical cord blood transplantation
Procedure: umbilical cord blood transplantation
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00025038

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: arsenic trioxide
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00045565

Locations: 🇺🇸
New Approaches to Brain Tumor Therapy Consortium, Baltimore, Maryland, United States

Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IV Ovarian Epithelial Cancer
Stage IV Primary Peritoneal Cavity Cancer

Interventions: Drug: fenretinide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00026091

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Erythroid Leukemia (M6)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)

Interventions: Drug: tipifarnib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 125

Registration Number: NCT00027872

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

Phase 1

Withdrawn

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-22

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00030355

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Celecoxib in Preventing Skin Cancer

Phase 2

Withdrawn

Conditions: Non-melanomatous Skin Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-22

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00025051

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Bronchoalveolar Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: gefitinib
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00029003

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma

Interventions: Biological: aldesleukin
Biological: filgrastim
Drug: cyclophosphamide
Drug: etoposide
Radiation: radiation therapy
Procedure: peripheral blood stem cell transplantation
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 206

Registration Number: NCT00002649

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

Home Terms & Conditions Privacy Policy